Company news

Share this article:
According to an internal memo, Pfizer is planning to end manufacturing of heart disease medications, Forbes reported, while also scaling back development of anemia, osteoporosis, liver, muscle, obesity and peripheral artery disease treatments. The company will instead focus on five therapeutic areas: Alzheimer's; diabetes, immune disorders and inflammation; cancer; pain and mental illness.

In an effort to control costs, GlaxoSmithKline may cut as many as 850 R&D jobs in the US and UK, according to a Wall Street Journal report.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.